INDOCONSEIndoco Remedies Limited· PharmaceuticalsHighNeutral
Announced Mon, 18 May · 20:11 IST

Indoco Remedies Limited has informed the Exchange about Completion of transfer of its Ophthalmic Division to Sunways (India) Private Limited

Core Business DivestedStrategic Transactions View source PDF

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹214.96
prior close
₹215.26
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.3-0.1-0.3-2.0-4.7-7.0-9.0-10.7-2.3-4.6+8.5+13.9
Up moveDown movePending
AI summary

Indoco Remedies has completed the sale and transfer of its Ophthalmic Division to Sunways (India) Private Limited as a going concern on a slump sale basis. The transfer was executed on May 18, 2026, following the approval and execution of an Agreement to Transfer Business (ATB) dated April 30, 2026. The deal covers operations across India and 15 African countries including Benin, Kenya, Tanzania, Zimbabwe, and others. All conditions precedent specified in the ATB were fulfilled prior to completion.

Likely market impact

The completion marks the successful exit of Indoco Remedies from its ophthalmic business segment. Shareholders should note this is a strategic portfolio restructuring rather than a distress sale, as conditions were fully satisfied before completion.